

## Domagrozumab

Cat. No.:	HY-P99857
CAS No.:	1629605-31-7
Target:	TGF-beta/Smad
Pathway:	Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Domagrozumab is an anti-myostatin humanized monoclonal antibody with a $K_D$ value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) <sup>[1]</sup> .
<b>In Vitro</b>	Domagrozumab (PF-06252616) inhibits human myostatin signaling activity with an $IC_{50}$ value of $< 1$ nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Domagrozumab (PF-06252616; 10 and 30 mg/kg; i.v.) increases myostatin levels in a dose-dependent manner and induces skeletal muscle hypertrophy in cynomolgus monkeys <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. St Andre M, et, al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017 Nov 9;7(1):25.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA